References
- Ao S., Shingu Y., Notsu Y., Kikuchi C., Yamaguchi I. Characterization of a novel aldose reductase inhibitor, FR74366. Proceedings of the Japan-US Aldose Reductase Workshop, N. Sakamoto, J. H. Kinoshita, P. F. Kador, N. Hotta. Excerpta Medica, Amsterdam 1990; 81–88
- Kanamaru M., Mizuno A., Nagashima S., Umetsu J., Nakashima M., Terakawa M., Sugiyama A. Pharmacokinetics of FK366 and its effect on aldose reductase and serum uric acid in healthy volunteers. European Journal of Clinical Pharmacology 1989; 30: A315, (Suppl)
- Gillette J. R. The problem of chemically reactive metabolites. Drug Metabolism Reviews 1982; 13: 941–961
- Kato R. Drug metabolism under pathological and abnormal physiological states in animals and man. Xenobiotica 1977; 7: 25–92
- Smith D. A., Humphery M. J., Charuel C. Design of toxicokinetic studies. Xenobiotica 1990; 20: 1187–1199
- Tanaka Y., Fujiwara T., Esumi Y. Sex difference in the excretion of zenarestat in mouse, rat, dog and man. Xenobiotica 1992b; 22: 941–947
- Tanaka Y., Sekiguchi T., Sawamoto T., Katami T., Ueda Y., Esumi Y., Noda K. Absorption, distribution and excretion of zenarestat, a new aldose reductase inhibitor, in rat and dog. Xenobiotica 1992a; 22: 57–64
- Yamano K., Ishibashi K., Tanaka Y., Tokuma Y., Noda K., Shiogai Y. The quantitative method of FR74366 and FR74366 1-O-acylglucuronide in human plasma and urine. Xenobiotic Metabolism and Disposition 1990; 5: 69